JP2025504478A5 - - Google Patents

Info

Publication number
JP2025504478A5
JP2025504478A5 JP2024543149A JP2024543149A JP2025504478A5 JP 2025504478 A5 JP2025504478 A5 JP 2025504478A5 JP 2024543149 A JP2024543149 A JP 2024543149A JP 2024543149 A JP2024543149 A JP 2024543149A JP 2025504478 A5 JP2025504478 A5 JP 2025504478A5
Authority
JP
Japan
Prior art keywords
aav
sequence
aav vector
vector genome
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/050426 external-priority patent/WO2023139496A1/en
Publication of JP2025504478A publication Critical patent/JP2025504478A/ja
Publication of JP2025504478A5 publication Critical patent/JP2025504478A5/ja
Pending legal-status Critical Current

Links

JP2024543149A 2022-01-21 2023-01-18 ゴーシェ病の遺伝子療法 Pending JP2025504478A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263267046P 2022-01-21 2022-01-21
US63/267,046 2022-01-21
US202263382502P 2022-11-05 2022-11-05
US63/382,502 2022-11-05
PCT/IB2023/050426 WO2023139496A1 (en) 2022-01-21 2023-01-18 Gene therapy for gaucher disease

Publications (2)

Publication Number Publication Date
JP2025504478A JP2025504478A (ja) 2025-02-12
JP2025504478A5 true JP2025504478A5 (cg-RX-API-DMAC7.html) 2026-01-26

Family

ID=85122738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543149A Pending JP2025504478A (ja) 2022-01-21 2023-01-18 ゴーシェ病の遺伝子療法

Country Status (11)

Country Link
US (1) US20250257367A1 (cg-RX-API-DMAC7.html)
EP (1) EP4465998A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504478A (cg-RX-API-DMAC7.html)
KR (1) KR20240134991A (cg-RX-API-DMAC7.html)
AU (1) AU2023208274A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248631A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024011137A2 (cg-RX-API-DMAC7.html)
IL (1) IL314294A (cg-RX-API-DMAC7.html)
MX (1) MX2024009003A (cg-RX-API-DMAC7.html)
TW (1) TWI874898B (cg-RX-API-DMAC7.html)
WO (1) WO2023139496A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR134407A1 (es) * 2023-11-15 2026-01-14 Genzyme Corp Métodos de tratamiento de la enfermedad de gaucher y de la enfermedad de parkinson gba

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
NZ716102A (en) 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
CN111542549A (zh) * 2017-10-03 2020-08-14 普利维尔治疗公司 用于溶酶体障碍的基因疗法
TW202005978A (zh) * 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
AU2019300431A1 (en) * 2018-07-13 2021-01-14 Ucl Business Ltd Glucocerebrosidase gene therapy
JP7664848B2 (ja) * 2019-04-10 2025-04-18 プリベイル セラピューティクス,インコーポレーテッド リソソーム障害のための遺伝子療法
WO2021102107A1 (en) * 2019-11-19 2021-05-27 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
IL296662A (en) * 2020-03-24 2022-11-01 Generation Bio Co Non-viral dna vectors and uses thereof for expressing gaucher therapeutics

Similar Documents

Publication Publication Date Title
JP2025179046A5 (cg-RX-API-DMAC7.html)
JP2026027271A5 (cg-RX-API-DMAC7.html)
US10392632B2 (en) AAV8 vector with enhanced functional activity and methods of use thereof
US5658785A (en) Adeno-associated virus materials and methods
JP2024009857A5 (cg-RX-API-DMAC7.html)
JP2021523718A5 (cg-RX-API-DMAC7.html)
JP2021533805A5 (cg-RX-API-DMAC7.html)
RU2018129159A (ru) Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
EP4071245A1 (en) Factor ix gene therapy
EP1546343B1 (en) High titer recombinant aav production
JP2023503850A5 (cg-RX-API-DMAC7.html)
JP2023509443A5 (cg-RX-API-DMAC7.html)
JP7707081B2 (ja) 網膜細胞を標的とした最適化された遺伝子治療
JP2024504611A5 (cg-RX-API-DMAC7.html)
JP2022533448A5 (cg-RX-API-DMAC7.html)
JP2025510017A5 (cg-RX-API-DMAC7.html)
JP2023551911A5 (cg-RX-API-DMAC7.html)
JP2023545384A5 (cg-RX-API-DMAC7.html)
RU2021134508A (ru) Интратекальная и внутривенная комбинированная генная терапия для лечения болезни баттена у детей
EP4198046A1 (en) Alpha-sarcoglycan gene transfer increase using modified itr sequences
JP2024546578A5 (cg-RX-API-DMAC7.html)
KR20250143161A (ko) 시누클레인병증의 치료를 위한 유전자 요법
RU2021121087A (ru) Способы и композиции для лечения болезней накопления гликогена
JP2024517737A5 (cg-RX-API-DMAC7.html)
JP2025508743A5 (cg-RX-API-DMAC7.html)